Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.55 |
| ▸ | KDR | P35968 | 10/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826831 | 0.88 | KDR (0.49) | BRAFKDRMEN1KMT2AL3MBTL1 | |
| SCHEMBL826243 | 0.83 | KMT2A (0.54) | BRAFKDRMEN1KMT2APOLB | |
| SCHEMBL826668 | 0.83 | BRAF (0.63) | BRAFKDRRAF1MAPT | |
| SCHEMBL826773 | 0.80 | BRAF (0.84) | BRAFKDRMEN1KMT2APOLB | |
| SCHEMBL2194124 | 0.80 | DYRK1A (0.66) | KDRMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL826287 | 0.79 | BRAF (0.62) | BRAFKDRMEN1KMT2APOLB | |
| SCHEMBL823540 | 0.74 | BRAF (0.78) | BRAFKDRRAF1 | |
| SCHEMBL823671 | 0.73 | BRAF (0.69) | BRAFKDRDYRK1ARAF1 | |
| SCHEMBL825835 | 0.72 | BRAF (0.79) | BRAFKDRRAF1 | |
| SCHEMBL826107 | 0.72 | KDR (0.59) | BRAFKDRMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497274-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| US-8143258-B2 | Benzothiazole compounds useful for Raf inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885KDR 1130/4885MEN1 692/4885 |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885KDR 1130/4885MEN1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.